Evidence map›Paper›PMID 41968983›Full record

ReviewCancer biology & medicine2026

Artificial intelligence in breast cancer: applications and advancements.

Jianbin Li, Zefei Jiang

Abstract readReview
In one paragraph

Review in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jianbin LiSenior Department of Oncology, Chinese PLA General Hospital, Beijing 100071, China.
Zefei JiangSenior Department of Oncology, Chinese PLA General Hospital, Beijing 100071, China.ORCID 0000-0002-4295-0173

Funding

National Natural Science Foundation of China 82404074Science and Technology Major Project 2024ZD0519805
6 · The paper itself

Abstract

Breast cancer is the most common malignant tumor among women globally and poses a major public health challenge due to limitations in traditional diagnostic and treatment processes, such as subjective interpretation biases and inefficient multi-dimensional data integration. Artificial intelligence (AI), particularly deep learning and machine learning technologies, has emerged as a transformative tool in addressing these issues. Clinically, AI has been widely applied in imaging screening to improve detection rates and reduce reading time, digital pathology for precise tumor typing and gene mutation prediction, treatment decision-support systems to enhance guideline compliance, and drug research and development to accelerate target identification and virtual screening. Despite these achievements, AI implementation faces challenges, such as data standardization issues, limited model generalization, low clinical accessibility, and unclear ethical-legal responsibilities, which require targeted solutions that include national data standards, multi-center training, hierarchical physician training, and explainable AI. Future directions involve multi-modal data integration, human-AI collaborative multidisciplinary team models, and extension to full-cycle health management from prevention-to-rehabilitation. This review provides a systematic overview of the role of AI in breast cancer care, offering insights for clinical practice and scientific research innovation, and supporting the transition toward personalized and intelligent medicine in oncology.

Indexed as

Artificial IntelligenceBreast NeoplasmsFemaleHumansapplicationArtificial intelligencebreast cancerchallenge

Identifiers

PMID41968983
PMCPMC13059870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.